GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAREPTA THERAPEUTICS INC

Financial Performance:

• No specific Q3 financial metrics (revenue, earnings, cash flow, debt) were disclosed in the transcript; focus was strictly on operational and pipeline updates.
• The company leverages substantial revenue from its commercial Duchenne business to fund pipeline development without requiring equity raises.
• The PMO (Duchenne) business is described as "robust," generating reliable cash flow.

Guidance and Future Outlook:

• Management predicts 2027 will be a "transformational year" for the company.
• Long-term outlook includes the potential for accelerated approval for DMD (FSHD and DM1 programs) and proof of biology for Huntington's.
• Levitas (DMD gene therapy) growth trajectory is currently viewed as a "clean baseline" pending longer-term trends and upcoming data readouts (Cohort 8).
• The DM1 program is expected to provide updates later in the year, with a focus on biomarker-based proof of concept.

Business Segments and Product Lines:

• Duchenne (Dysferlin/Exon Skipping): Exon skipping therapies (specifically Exon 51) maintain high stickiness with 90% of patients receiving home-dosed treatments; strong safety profile and extensive real-world evidence (10+ years on market).
• Gene Therapy (Levitas): Positioned as a robust business; new long-term data (3-year, functional, imaging) has been disseminated to the field force to drive adoption.
• Neuromuscular Pipeline (DM1 & FSHD): Utilizes a unique delivery vehicle (alpha-B-beta-6 peptide ligand) achieving high muscle concentrations without dose-limiting toxicity; aiming for >20-25% DMPK knockdown in DM1 and >70% DUX4 inhibition in FSHD.
• Huntington's Disease (HD): Unique systemic delivery targeting CNS and deep brain nuclei via sub-Q dosing; proof of biology expected mid-next year.

Market and Competitive Landscape:

• DMD Competition: Faces potential competition from DYN (Dysferlin program) for Exon 51; competitive advantage relies on long-term safety data, established reimbursement pathways, and home-dosing convenience rather than just efficacy claims.
• Regulatory Standards: Emphasizes the FDA standard requiring randomized controlled data for gene therapies to demonstrate clinical benefit, rejecting reliance solely on microdystrophin expression correlates.
• Novartis/AMG Comparison: Contrasts Serapta's delivery system with Novartis's bispecific antibody approach, claiming Serapta can escalate doses higher without the anemia or receptor downregulation limitations observed in competitor programs.

Risks and Challenges:

• Competitive Pressure: New entrants (e.g., DYN) could challenge market share for new incident patients, though existing stable patients are expected to remain "sticky."
• Clinical Trial Uncertainty: Final approval thresholds for functional endpoints (e.g., VHOT) in DM1 and HD remain undefined; success is contingent on achieving specific biomarker knockdown levels.
• Timeline Risks: Huntington's data readout timeline was pushed to mid-next year to ensure sufficient data demonstrates proof of biological activity.
• Market Adoption: Physician and patient switching behavior depends on long-term stability and safety experiences rather than physician visits frequency.

Management Commentary and Tone:

• Tone is highly confident and strategic, emphasizing a "unique setup" where commercial cash flow drives a high-value pipeline without dilution.
• CEO Michael Severino expressed strong conviction in the durability of the Duchenne business and the transformative potential of the sRNA pipeline.
• Management dismissed concerns about the challenging 2025 performance, framing it as a year of strategic correction (focusing Levitas on ambulatory patients) now yielding a stable baseline.

Analyst Questions and Answers:

• Q: How does Exon 51 handle competition? A: Stickiness is driven by 10+ years of safety data, real-world evidence, and 90% home-dosing adherence; switching is a multi-disciplinary decision involving patient/family experience.
• Q: What are the targets for DM1? A: Management aims for >20-25% DMPK knockdown/splicing correction (surpassing the 10-15% range of competitors) to enable registration studies and potential accelerated approval.
• Q: Is FDA likely to approve Huntington's via accelerated pathway? A: Yes, if robust CNS knockdown and blood-brain barrier penetration are demonstrated, given the unmet need and novelty of systemic delivery.
• Q: Why was HD data delayed? A: To ensure the selected cohort provides the most convincing proof of biological activity regarding CNS impact.

Other Key Points:

• Delivery Technology: Serapta's use of the alpha-B-beta-6 peptide ligand allows for rapid internalization, recycling, and high muscle concentrations without receptor depletion or dose-limiting toxicity.
• Strategic Positioning: The company is pivoting from a pure commercial focus to a balanced model where commercial cash flow funds high-risk, high-reward pipeline assets (DM1, FSHD, HD).
• Biomarker Utility: Strong emphasis on using biomarkers (DMPK, DUX4, splicing correction) as primary drivers for regulatory discussions, potentially bypassing traditional functional endpoints for accelerated approval.
• Market Access: Robust patient support programs and access groups are highlighted as critical to maintaining high adherence rates.